Explore ss-31 calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.
Anonymized ss-31 calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.
SS-31 (elamipretide) is a mitochondria-targeted research peptide most often sourced for mitochondrial-health and recovery protocols. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1]
Cardiolipin binding by SS-31 preserves cristae architecture, optimizes electron-transport-chain coupling, reduces electron leakage to oxygen, and lowers mitochondrial reactive-oxygen-species generation. The end result is improved ATP synthesis efficiency in dysfunctional mitochondria, which is the basis for its pursuit in primary mitochondrial disease.
Elamipretide has been evaluated in primary mitochondrial myopathy (MMPOWER-3, Phase 3), heart failure with preserved ejection fraction (PROGRESS-HF), Barth syndrome (TAZPOWER, Phase 2/3), and Leber hereditary optic neuropathy.[2][3] MMPOWER-3 missed its primary endpoint in 2019; subsequent Barth syndrome work supported a pending FDA submission.
Not FDA-approved as of 2024 (NDA for Barth syndrome under FDA review). Research-grade SS-31 is for non-clinical use only.
SS-31 has a reported half-life of ~2–3 hours. The pharmacokinetic reference models an interval of once daily (subcutaneous); this is not a measured community cadence or a dosing recommendation. A few-hour plasma half-life means elamipretide clears between daily doses, but it concentrates in mitochondria where its effect outlasts the blood level. Pharmacokinetic source: Clinical PK for elamipretide (Stealth BioTherapeutics). It is catalogued under Performance Peptides on WPA.
10,041 SS-31 reconstitution calculations have been logged by the WPA community.
This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
WPA Analysis
SS-31 — also known as elamipretide (development codes Bendavia, MTP-131) — is a synthetic tetrapeptide developed out of the Hazel Szeto and Peter Schiller work at Cornell Medical College in the early 2000s. The molecular logic is unusually elegant. SS-31 is a four-amino-acid sequence (D-Arg-Dmt-Lys-Phe-amide, where Dmt is 2,6-dimethyltyrosine) that combines a strong net positive charge with substantial hydrophobicity — the combination drives selective concentration in the inner mitochondrial membrane by electrostatic binding to cardiolipin, the negatively charged mitochondrial-specific phospholipid that organizes the electron transport chain complexes. The peptide concentrates more than 1000-fold in mitochondria relative to cytosol, where it appears to stabilize cardiolipin-protein interactions, reduce mitochondrial reactive oxygen species production, and protect cristae structure under oxidative or ischemic stress.
The clinical-program record on SS-31 is the most clinically advanced of any non-FDA-approved peptide on this site. Stealth BioTherapeutics licensed the molecule and ran multiple Phase 2 and Phase 3 programs — MMPOWER-3 in primary mitochondrial myopathy (a 218-patient Phase 3 randomized trial that missed its primary 6-minute-walk-test endpoint at 24 weeks in 2019, with mixed results on secondary measures), ReCLAIM-2 in geographic atrophy / dry age-related macular degeneration (a Phase 2b program that read out positive on key imaging endpoints, with subsequent Phase 3 work in progress), the TAZPOWER program in Barth syndrome (an ultra-rare genetic mitochondrial disease, where elamipretide has received FDA Breakthrough Therapy designation and Stealth has pursued an NDA pathway), and earlier work in heart failure and ischemia-reperfusion injury. The Phase 3 protocol used 40mg subcutaneously once daily in primary mitochondrial myopathy. As of the time of writing, elamipretide has not yet received FDA approval for any indication, but the Barth syndrome program represents the most likely near-term path to a labeled product. That clinical record makes SS-31 the most evidence-supported peptide in the WPA mitochondrial / longevity group — the only compound on this page with a multi-year, multi-thousand-patient Phase 3 program behind it.
Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.
WPA DOSING INSIGHT
The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.
WPA RECONSTITUTION INSIGHT
Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.